bluebird bio, Inc. (BLUE): Price and Financial Metrics


bluebird bio, Inc. (BLUE): $7.37

-0.22 (-2.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BLUE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BLUE POWR Grades

  • Growth is the dimension where BLUE ranks best; there it ranks ahead of 87.5% of US stocks.
  • BLUE's strongest trending metric is Momentum; it's been moving up over the last 178 days.
  • BLUE's current lowest rank is in the Stability metric (where it is better than 0.51% of US stocks).

BLUE Stock Summary

  • BLUEBIRD BIO INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.17% of US listed stocks.
  • With a year-over-year growth in debt of 53.23%, BLUEBIRD BIO INC's debt growth rate surpasses 81.07% of about US stocks.
  • Revenue growth over the past 12 months for BLUEBIRD BIO INC comes in at -166.63%, a number that bests only 0.33% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to BLUE, based on their financial statements, market capitalization, and price volatility, are LYEL, SNAP, SITM, RKLB, and AI.
  • Visit BLUE's SEC page to see the company's official filings. To visit the company's web site, go to www.bluebirdbio.com.

BLUE Valuation Summary

  • In comparison to the median Healthcare stock, BLUE's price/sales ratio is 980% lower, now standing at -17.6.
  • BLUE's EV/EBIT ratio has moved up 11.3 over the prior 115 months.

Below are key valuation metrics over time for BLUE.

Stock Date P/S P/B P/E EV/EBIT
BLUE 2022-11-25 -17.6 4.0 -1.4 -1.9
BLUE 2022-11-23 -17.4 3.9 -1.4 -1.8
BLUE 2022-11-22 -16.5 3.7 -1.3 -1.8
BLUE 2022-11-21 -15.4 3.5 -1.2 -1.7
BLUE 2022-11-18 -16.2 3.6 -1.3 -1.7
BLUE 2022-11-17 -16.3 3.7 -1.3 -1.7

BLUE Growth Metrics

    Its 5 year revenue growth rate is now at 778.41%.
  • Its 3 year price growth rate is now at -97.68%.
  • Its year over year revenue growth rate is now at -102.97%.
BLUE's revenue has moved down $71,433,000 over the prior 52 months.

The table below shows BLUE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 -35.746 -436.405 -453.862
2022-06-30 -13.14 -506.318 -594.158
2022-03-31 -7.187 -557.608 -735.722
2021-12-31 3.662 -635.639 -819.378
2021-09-30 53.651 -651.107 -864.2
2021-06-30 50.247 -652.948 -842.129

BLUE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BLUE has a Quality Grade of D, ranking ahead of 15.84% of graded US stocks.
  • BLUE's asset turnover comes in at 0.029 -- ranking 353rd of 682 Pharmaceutical Products stocks.
  • NERV, OTLC, and BPMC are the stocks whose asset turnover ratios are most correlated with BLUE.

The table below shows BLUE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.029 0.594 -0.648
2021-03-31 0.129 0.972 -0.495
2020-12-31 0.136 0.978 -0.496
2020-09-30 0.137 0.980 -0.528
2020-06-30 0.132 0.981 -0.546
2020-03-31 0.030 0.934 -0.590

BLUE Price Target

For more insight on analysts targets of BLUE, see our BLUE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $82.33 Average Broker Recommendation 1.92 (Hold)

BLUE Stock Price Chart Interactive Chart >

Price chart for BLUE

BLUE Price/Volume Stats

Current price $7.37 52-week high $11.70
Prev. close $7.59 52-week low $2.87
Day low $7.27 Volume 2,297,500
Day high $7.74 Avg. volume 5,351,413
50-day MA $6.56 Dividend yield N/A
200-day MA $5.29 Market Cap 611.05M

bluebird bio, Inc. (BLUE) Company Bio


Bluebird Bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies. The company was founded in 1992 and is based in Cambridge, Massachusetts.


BLUE Latest News Stream


Event/Time News Detail
Loading, please wait...

BLUE Latest Social Stream


Loading social stream, please wait...

View Full BLUE Social Stream

Latest BLUE News From Around the Web

Below are the latest news stories about BLUEBIRD BIO INC that investors may wish to consider to help them evaluate BLUE as an investment opportunity.

2 Growth Stocks That Could Double in 2023

Investing in biotech companies, especially relatively small ones, can be a double-edged sword. With that in mind, let's look at two gene-editing-focused biotechs that could perform substantially better next year: CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE). Right now, CRISPR Therapeutics is a clinical-stage biotech.

Yahoo | November 17, 2022

Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates

Bluebird (BLUE) delivered earnings and revenue surprises of 28.13% and 96.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 7, 2022

bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

SOMERVILLE, Mass., November 07, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the third quarter ended September 30, 2022 and shared recent operational progress.

Yahoo | November 7, 2022

bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference

SOMERVILLE, Mass., November 02, 2022--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 31st Annual Credit Suisse Healthcare Conference, Tuesday, November 8, at 5:00 p.m. PT at the Terranea Resort, Rancho Palos Verdes, CA.

Yahoo | November 2, 2022

Earnings Preview: Fstar Therapeutics, Inc. (FSTX) Q3 Earnings Expected to Decline

Fstar Therapeutics, Inc. (FSTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 2, 2022

Read More 'BLUE' Stories Here

BLUE Price Returns

1-mo 18.11%
3-mo 26.20%
6-mo 139.29%
1-year -28.65%
3-year -90.89%
5-year -95.73%
YTD -26.23%
2021 -76.91%
2020 -50.69%
2019 -11.54%
2018 -44.30%
2017 188.65%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6209 seconds.